Study wrapper · #602
The Safety and Efficacy of Growth Hormone Secretagogues.
Editor's note
This is a narrative review of the safety and efficacy of growth hormone secretagogues (GHS), the class that includes GH-releasing peptides such as hexarelin and the oral agent ibutamoren. The authors emphasize that GHS promote pulsatile GH release subject to negative feedback, which may avoid the supratherapeutic GH levels seen with GH injection. They note reported effects on appetite, lean mass, fat-free mass, bone turnover, and sleep, but stress that few long-term, rigorously controlled human trials exist, that insulin sensitivity may decrease with elevated blood glucose, and that long-term safety, including cancer risk, is unresolved. As class-level context it is genuinely useful; it is a review, not primary evidence, and the human data it summarizes remain limited and mixed. Hexarelin is not the sole focus.
Plain-language abstract
This is a review article summarizing what is known about the safety and effectiveness of growth hormone secretagogues, a group of compounds that prompt the body to release its own growth hormone. Hexarelin belongs to this group. The authors explain that these agents encourage a natural, self-limiting pulse of growth hormone, which may avoid the excessive levels caused by injecting growth hormone directly. Reported benefits across studies include increased appetite, more lean and fat-free mass, changes in bone turnover, and better sleep. Importantly, the authors caution that few long, well-controlled human trials exist, that blood sugar may rise as insulin sensitivity falls, and that long-term safety, including any cancer risk, is not yet established. This is a review of mostly limited human evidence, so firm conclusions are not possible.